15. Supplemental Disclosures Prepaid Expenses Prepaid expenses consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
Prepaid external research and development expenses |
|
$ |
7,957 |
|
|
$ |
6,410 |
|
Prepaid external general and administrative expenses |
|
|
2,584 |
|
|
|
3,969 |
|
Other |
|
|
1,363 |
|
|
|
1,548 |
|
|
|
$ |
11,904 |
|
|
$ |
11,927 |
|
Other Current Assets Other current assets consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
Net cost reimbursement due from AbbVie |
|
$ |
10,536 |
|
|
$ |
10,871 |
|
Accrued interest on investments |
|
|
348 |
|
|
|
1,004 |
|
Other |
|
|
873 |
|
|
|
1,030 |
|
|
|
$ |
11,757 |
|
|
$ |
12,905 |
|
Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
Accrued personnel costs |
|
$ |
12,959 |
|
|
$ |
17,418 |
|
Accrued external research and development expenses |
|
|
6,323 |
|
|
|
10,229 |
|
Accrued external general and administrative expenses |
|
|
2,028 |
|
|
|
1,301 |
|
Accrued royalties and sublicense fees |
|
|
964 |
|
|
|
8,652 |
|
Accrued purchases of property and equipment |
|
|
46 |
|
|
|
33 |
|
Other |
|
|
753 |
|
|
|
757 |
|
|
|
$ |
23,073 |
|
|
$ |
38,390 |
|
|